LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・ADMA Biologics Inc

ADMA Biologics Inc

Closed

SectorHealthcare

8.22 -2.61

Buy Sell

Overview

Share price change

24h

Current

Min

8.18

Max

8.26

Key metrics
By Trading Economics
Income	-4.1M 45M
Sales	-25M 114M
P/E Sector Avg	12.324 49.701
EPS	0.17
Profit margin	39.59
Employees	640
EBITDA	-13M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+187.26% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-453M 1.9B
Previous open	10.83
Previous close	8.22

News Sentiment

By Acuity

85%

15%

324 / 345 Ranking in Healthcare

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 maj 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 maj 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 maj 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 maj 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 maj 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 maj 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 maj 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 maj 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 maj 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 maj 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 maj 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 maj 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 maj 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 maj 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 maj 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 maj 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 maj 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 maj 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 maj 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 maj 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 maj 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 maj 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

187.26% upside

12 Months Forecast

Average 23.67 USD 187.26%

High 30 USD

Low 20 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Sentiment

By Acuity

324 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.